CLC Number:
| [1] |
Gupta D, Lee Chuy K, Yang J C, et al. Cardiovascular and metabolic effects of androgen-deprivation therapy for prostate cancer[J]. J Oncol Pract, 2018,14(10):580-587.
pmid: 30312560 |
| [2] |
Farrell SO, Garmo H, Holmberg L, et al. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer[J]. J Clin Oncol, 2015,33(11):1243-1251.
pmid: 25732167 |
| [3] |
Conteduca V, Lorenzo GD, Tartarone A, et al. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: An unresolved controversy[J]. Crit Rev Oncol Hematol, 2013,86(1):42-51.
doi: 10.1016/j.critrevonc.2012.09.008 pmid: 23092636 |
| [4] | Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer[J]. J Clin Oncol, 2006,24(27):4448-4456. |
| [5] |
Nanda A, Chen MH, Braccioforte MH, et al. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction[J]. JAMA, 2009,302(8):866-873.
doi: 10.1001/jama.2009.1137 pmid: 19706860 |
| [6] |
Keating NL, O’Malley AJ, Freedland SJ, et al. Diabetes and cardiovascular disease during androgen deprivation therapy: Observational study of veterans with prostate cancer[J]. J Natl Cancer Inst, 2010,102(1):39-46.
pmid: 19996060 |
| [7] |
Zhao J, Zhu S, Sun L, et al. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: A meta-analysis of population-based observational studies[J]. PLoS One, 2014,9(9):e107516.
doi: 10.1371/journal.pone.0107516 pmid: 25264674 |
| [8] | Bosco C, Bosnyak Z, Malmberg A, et al. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: A meta-analysis[J]. Eur Urol, 2015,68(3):386-396. |
| [9] | Meng F, Zhu S, Zhao J, et al. Stroke related to androgen deprivation therapy for prostate cancer: A meta-analysis and systematic review[J]. BMC Cancer, 2016,16(1):180. |
| [10] | Elagizi A, Köhler TS, Lavie CJ. Testosterone and cardiovascular health[J]. Mayo Clin Proc, 2018,93(1):83-100. |
| [11] |
Clinton TN, Woldu SL, Raj GV. Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer[J]. Expert Opin Pharmacother, 2017,18(8):825-832.
doi: 10.1080/14656566.2017.1328056 pmid: 28480768 |
| [12] |
Albertsen PC, Klotz L, Tombal B, et al. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist[J]. Eur Urol, 2014,65(3):565-573.
pmid: 24210090 |
| [13] |
Margel D, Peer A, Ber Y, et al. Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease[J]. J Urol, 2019,202(6):1199-1208.
pmid: 31188734 |
| [14] | A trial comparing cardiovascular safety of degarelix versus leuprolide in patients with advanced prostate cancer and cardiovascular disease(PRONOUNCE)[Z/OL]. (2016-01-26)[2020-04-06]. https://clinicaltrials.gov/ct2/show/NCT02663908?term=NCT02663908&draw=2&rank=1. |
| [15] | Cone EB, Marchese M, Reese S, et al. Lower odds of cardiac events for gonadotrophin-releasing hormone antagonists versus agonists[J/OL]. BJU Int, 3(2020-03-30)[2020-04-10]. https://pubmed.ncbi.nlm.nih.gov/32232935/?from_single_result=Lower+Odds+of+Cardiac+Events+for+Gonadotropic+Releasing+Hormone+Antagonists+versus+Agonists&expanded_search_query=Lower+Odds+of+Cardiac+Events+for+Gonadotropic+Releasing+Hormone+Antagonists+versus+Agonists. |
| [16] | Bubley GJ. Is the flare phenomenon clinically significant?[J]. Urology, 2001,58(2):5-9. |
| [17] | Knutsson A, Hsiung S, Celik S, et al. Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE-/- mice[J]. Sci Rep, 2016,6(1):26220. |
| [18] | Libby P. Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis[J]. J Lipid Res, 2009,50(Suppl):352-357. |
| [19] |
Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: A 12-month, comparative, randomized, open-label, parallel-group phase Ⅲ study in patients with prostate cancer[J]. BJU Int, 2008,102(11):1531-1538.
pmid: 19035858 |
| [20] |
Zareba P, Duivenvoorden W, Leong DP, et al. Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism?[J]. Ther Adv Urol, 2016,8(2):118-129.
doi: 10.1177/1756287215617872 |
| [21] | Wang Q, Zhou J, Yao W, et al. Follicle-stimulating hormone is responsible for androgen deprivation therapy associated atherosclerosis by exaggerating endothelial inflammation[J]. Eur Urol, 2019,18(Suppl 1):e72. |
| [22] |
Bhatia N, Santos M, Jones LW, et al. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer[J]. Circulation, 2016,133(5):537-541.
pmid: 26831435 |
| [1] | BAI Gao-chen,SONG Yi,JIN Jie,YU Wei,HE Zhi-song. Clinical efficacy of docetaxel combined with carboplatin in patients with metastatic castration-resistant prostate cancer [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 686-691. |
|
||